CommercialCoverageMedium impact
08.02.47b, linvoseltamab-gcpt (Lynozyfic™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
A new commercial policy for linvoseltamab-gcpt (Lynozyfic™) has been posted, which is a newly FDA-approved medication requiring updated billing and coverage guidelines. This affects pharmacy benefit billing for this specialty oncology drug.
Action Required
By April 1, 2026: Billing team must review and implement the new policy guidelines for linvoseltamab-gcpt (Lynozyfic™) billing procedures. Update billing system with any prior authorization requirements or coverage criteria specified in the full policy. Coordinate with pharmacy benefit management for proper claim submission protocols.